Drugs / Doxorubin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT04914390 | Sep 2023 → Mar 2025 | triple-negative breast carcinoma | Sichuan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04499118 | Aug 2020 → Aug 2021 | Her2-receptor negative breast cancer | Sichuan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02182687 | Jun 2014 → Oct 2021 | hepatocellular carcinoma | Lahey Clinic | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03960008 | Mar 2020 → Feb 2024 | hepatocellular carcinoma | Lahey Clinic | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doxorubin | “Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.” NCT04914390 ↗3“Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d” NCT04499118 ↗ |